Skip to main content

Table 2 Number of irAEs grouped by 18 tissue or organ disorders for FDA-approved ICIs

From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

 

Cemiplimab

Nivolumab

Pembrolizumab

Atezolizumab

Avelumab

Durvalumab

Ipilimumab

Number/ratio

Number/ ratio

Number/ ratio

Number/ ratio

Number/ratio

Number/ ratio

Number/ratio

BL

49/0.078

4,336/0.051

2,975/0.057

2,070/0.097

163/0.064

604/0.075

438/0.054

CD

35/0.056

3,947/0.046

2,117/0.040

1,074/0.050

151/0.060

435/0.054

561/0.069

ELD

1/0.002

382/0.004

177/0.003

93/0.004

7/0.003

29/0.004

18/0.002

EnD

25/0.040

4,346/0.051

2,234/0.043

848/0.040

124/0.049

289/0.036

289/0.036

ED

8/0.013

1,664/0.019

919/0.018

269/0.013

27/0.011

108/0.013

78/0.010

GD

62/0.099

11,231/0.131

6,505/0.124

3,093/0.145

357/0.141

939/0.117

1,233/0.152

HD

50/0.080

4,666/0.055

3,009/0.057

1,405/0.066

133/0.053

463/0.058

553/0.068

ID

33/0.053

1,539/0.018

1,151/0.022

366/0.017

60/0.024

84/0.010

98/0.012

MnD

39/0.062

6,095/0.071

3,012/0.058

1,494/0.070

173/0.068

342/0.043

490/0.060

McD

30/0.048

5,544/0.065

3,280/0.063

1,029/0.048

145/0.057

418/0.052

335/0.041

NMU

36/0.057

10,113/0.118

6,764/0.129

1,121/0.053

153/0.060

1,008/0.126

1,781/0.220

NsD

69/0.110

7,168/0.084

4,278/0.082

1,990/0.093

243/0.096

627/0.078

559/0.069

PD

16/0.025

1,836/0.021

1,136/0.022

381/0.018

45/0.018

148/0.018

159/0.020

RuD

31/0.49

3,827/0.045

2,661/0.051

1,261/0.059

162/0.064

259/0.032

382/0.047

RB

3/0.005

259/0.003

205/0.004

95/0.004

6/0.002

20/0.002

14/0.002

RTM

73/0.116

9,317/0.109

5,755/0.110

2,429/0.114

277/0.110

1,526/0.190

849/0.105

SSD

40/0.064

6,631/0.078

4,414/0.084

1,362/0.064

168/0.066

439/0.055

1/0.000

VD

28/0.045

2,550/0.030

1,743/0.033

918/0.043

135/0.053

283/0.035

271/0.033

Total number cases

628

85,451

52,335

21,298

2,529

8,021

8,109